Classifications

• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
  • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
  • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
  • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
  • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
  • C07D239/47—One nitrogen atom and one oxygen or sulfur atom, e.g. cytosine
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
  • C07C275/00—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups
  • C07C275/28—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
  • C07C275/32—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton being further substituted by singly-bound oxygen atoms
  • C07C275/34—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton being further substituted by singly-bound oxygen atoms having nitrogen atoms of urea groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
  • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
  • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
  • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
  • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
  • C07D239/52—Two oxygen atoms
  • C07D239/54—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals
  • C07D239/545—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals with other hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms

Definitions

• This invention relates to a process of making di-aryl urea compounds of formula (I):
• Ri, R 2 , R 3 , X and of fora ⁇ ula(I) are defined below.
• the compounds inhibit production of cytokines involved in inflammatory processes and are thus useful for treating diseases and pathological conditions involving inflammation such as chronic inflammatory disease.
• WO 98/52558 discloses heteroaryl urea compounds which are indicated to be useful in treating cytokine mediated diseases.
• WO 99/23091 discloses another class of urea compounds which are useful as anti-inflammatory agents.
• WO 99/32463 relates to aryl ureas amd their use in treating cytokine diseases and proteolytic enzyme mediated disease.
• WO 00/41698 discloses aryl ureas said to be useful in treating p38 MAP kinase diseases.
• Ri, R 2 , R 3 , X and W of formula(I) are defined therein.
• the compounds inhibit production of cytokines involved in inflammatory processes and are thus useful for treating diseases and pathological conditions involving inflammation. Also disclosed are processes for preparing compounds of the formula (I).
• the advantage provided by the present invention allows reducing the synthetic sequence to three steps and overcome low yields and exothermic conditions.
• Ri is Cl-10 alkyl branched or unbranched or C3-10 cycloalkyl each optionally partially or full halogenated;
• R 2 Cl-10 alkyl branched or unbranched, Cl-10 alkoxy branched or unbranched, C3-10 cycloalkyl each optionally partially or full halogenated and optionally substituted by aryl or R 2 is aryl;
• R 3 is attached at the 3- or 4-position on the phenyl ring and is hydrogen, Cl-10 alkyl, carbocycle, heterocycle, heteroaryl or R 4 -S(O) 2 -NH- wherein j is chosen from C 1-5 alkyl or carbocycle;
• Ri is chosen from Cl-5 alkyl or Cl-5 alkoxy
• R a is independently chosen from hydrogen, Cl-5 alkyl, aryl, arylCl-3 alkyl, C3-7cycloalkyl, C3-7cycloalkyl Cl-3 alkyl, Cl-5alkoxyCl-5alkyl and heterocyclyl Cl-3 alkyl wherein the heterocycyl is chosen from tetrahydrofuran, pyrrolidinyl and morpholinyl, each R a where possible is optionally substituted by one to two Cl-5 alkyl, Cl-5 alkoxy or amino di-substituted by Cl-5 alkyl;
• preferred solvents are NMP, DMSO, THF, EtOAc, Dioxane; preferred aprotic bases are N-methylpyrrolidinone, N-methylpyrrolidine, triethylamine
• a preferred temperature is about 45°C.
• Yi is halogen chosen from Cl, Br, I and F and Y 2 is halogen chosen from Cl and F.
• Yi is Cl and Y 2 is Cl.
• preferred solvents are Cl-5 alcohol, preferably ethanol; preferred aprotic bases are carbonates such as Na 2 CO 3 ; preferred time is 24h; and a preferred temperature is about 45°C.
• preferred solvents are Dioxane, Toluene, TGME, Triethylene glycol, preferably TGME (tri(ethylene glycol) monomethyl ether), KF; preferred time is 18h; and a preferred temperature is about 60°C.
• the invention provides a process of making compounds of the formula (I) as described immediately above and wherein Rx is -CF 3 , -CH(CH 3 XCF 3 ), -CH(CF 3 ) 2 , -OCF 3 , -CF 2 CF 3 ; R 2 is -O-C 1-5 alkyl; R 3 is hydrogen or R 4 -S(O) 2 -NH- wherein R 4 is chosen from C ⁇ -5 alkyl or carbocycle;
• Rj is chosen from Cl-4 alkyl or C 1-4 alkoxy.
• the invention provides a process of making compounds of the formula (I) as described immediately above and wherein Ri is -CF 3 , -CH(CH 3 )(CF 3 ), -CH(CF 3 ) 2 , -OCF 3 or -CF 2 CF 3 ;
• R 2 is -O-C 1-3 alkyl
• R a is independently chosen from hydrogen, Cl-5 alkyl, phenylCl-3 alkyl, C3-6cycloalkyl, C3-6cycloalkyl Cl-3 alkyl, Cl-3alkoxyCl-3alkyl and heterocyclyl Cl-3 alkyl wherein the heterocycyl is chosen from tetrahydrofuran, pyrrolidinyl and morpholinyl, each R a where possible is optionally substituted by one to two Cl-3 alkyl, Cl-3 alkoxy or amino di-substituted by Cl-2 alkyl;
• Ri is chosen from Cl-3 alkyl or Cl-3 alkoxy.
• the invention provides a process of making compounds of the formula (I) as described immediately above and wherein Ri is -CF 3 , -CH(CH 3 )(CF 3 ), -CH(CF 3 ) 2 or -CF 2 CF 3 ;
• R 2 is -O-C 1-2 alkyl
• Rj is chosen from Cl-2 alkyl or Cl-2 alkoxy.
• the invention provides a process of making compounds of the formula (I) as described immediately above and wherein
• R 2 is -O-CH 3 .
• Rj is methyl or methoxy.
• the invention provides a process of making compounds of the formula (I) as described immediately above and wherein
• R t is methyl
• N(Ra)2 is : NH 2 , NH(CH 3 ), -NHCH 2 CH 2 N(CH 3 ) 2 , -NHCH 2 CH 2 -O-CH 3 , -NH-CH 2 -N(CH 3 ) 2) -
• Preferred intermediate compounds include:
• Cl-3 alkoxy is a Cl-3(not an example used) alkyl with a terminal oxygen, such as methoxy, ethoxy, propoxy.
• All alkyl, alkenyl and alkynyl groups shall be understood as being branched or unbranched where structurally possible and unless otherwise specified. Other more specific definitions are as follows:
• Carbocycles include hydrocarbon rings containing from three to ten carbon atoms. These carbocycles may be either aromatic and non-aromatic ring systems. The non-aromatic ring systems may be mono- or polyunsaturated. Preferred carbocycles include but are not limited to cyclopropyl, cyclobutyl, cyclopentyl, cyclopentenyl, cyclohexyl, cyclohexenyl, cycloheptanyl, cycloheptenyl, phenyl, indanyl, indenyl, benzocyclobutanyl, dihydronaphthyl, tetrahydronaphthyl, naphthyl, decahydronaphthyl, benzocycloheptanyl and benzocycloheptenyl. Certain terms for cycloalkyl such as cyclobutanyl and cyclobutyl shall be used inerchangeably.
• heterocycle refers to a stable nonaromatic 4-8 membered (but preferably, 5 or 6 membered) monocyclic or nonaromatic 8-11 membered bicyclic heterocycle radical which may be either saturated or unsaturated.
• Each heterocycle consists of carbon atoms and one or more, preferably from 1 to 4 heteroatoms chosen from nitrogen, oxygen and sulfur.
• the heterocycle may be attached by any atom of the cycle, which results in the creation of a stable structure.
• heterocycles include but are not limited to, for example oxetanyl, pyrrolidinyl, tetrahydrofuranyl, tetrahydrothiophenyl, piperidinyl, piperazinyl, morpholinyl, tetrahydropyranyl, dioxanyl, tetramethylene sulfonyl, tetramethylene sulfoxidyl, oxazolinyl, thiazolinyl, imidazolinyl, tertrahydropyridinyl, homopiperidinyl, pyrrolinyl, tetrahydropyrimidinyl, decahydroquinolinyl, decahydroisoquinolinyl, thiomorpholinyl, thiazolidinyl, dihydrooxazinyl, dihydropyranyl, oxocanyl, heptacanyl, thioxany
• heteroaryl shall be understood to mean an aromatic 5-8 membered monocyclic or 8-11 membered bicyclic ring containing 1-4 heteroatoms such as N,O and S. Unless otherwise stated, such heteroaryls include: pyridinyl, pyridonyl, quinolinyl, dihydroquinolinyl, tetrahydroquinoyl, isoquinolinyl, tetrahydroisoquinoyl, pyridazinyl, pyrimidinyl, pyrazinyl, benzimidazolyl, benzthiazolyl, benzoxazolyl, benzofiiranyl, benzothiophenyl, benzpyrazolyl, dihydrobenzofuranyl, dihydrobenzothiophenyl, benzooxazolonyl, benzo[l,4]oxazin-3-onyl, benzodioxolyl, benzo[l,3]d
• aryl or heterocycle unless otherwise specified includes it's partially hydrogenated derivative.
• pyrrolidinyl may include pyrrolinyl
• phenyl may include it's hydrogenated derivatives such as cyclohexenyl.
• Other partially or fully hydrogenated derivatives will be apparent to one of ordinary skill in the art.
• one or more carbon atoms can be optionally replaced by heteroatoms: O, S or N. It shall be understood that if N is not substituted then it is NH, it shall also be understood that the heteroatoms may replace either terminal carbon atoms or internal carbon atoms within a branched or unbranched carbon chain.
• Such groups can be substituted as herein above described by groups such as oxo to result in defintions such as but not limited to: alkoxycarbonyl, acyl, amido and thioxo.
• nitrogen and sulfur include any oxidized form of nitrogen and sulfur and the quaternized form of any basic nitrogen.
• halogen as used in the present specification shall be understood to mean bromine, chlorine, fluorine or iodine, preferably fluorine.
• the compounds of the invention are only those which are contemplated to be 'chemically stable' as will be appreciated by those skilled in the art.
• a compound which would have a 'dangling valency', or a 'carbanion' are not compounds contemplated by the inventive methods disclosed herein.

Landscapes

• Chemical & Material Sciences (AREA)
• Organic Chemistry (AREA)
• Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
• Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
• Plural Heterocyclic Compounds (AREA)

Priority Applications (3)

Applications Claiming Priority (2)

Publications (1)

Family

ID=34061980

Family Applications (1)

Country Status (6)

Cited By (4)

Families Citing this family (2)

Citations (3)

• 2004
  • 2004-06-11 WO PCT/US2004/018694 patent/WO2005005396A1/en not_active Ceased
  • 2004-06-11 JP JP2006518643A patent/JP2007518680A/ja active Pending
  • 2004-06-11 EP EP04755070A patent/EP1644341A1/en not_active Withdrawn
  • 2004-06-11 CN CNA2004800184368A patent/CN1812975A/zh active Pending
  • 2004-06-11 CA CA002530776A patent/CA2530776A1/en not_active Abandoned
  • 2004-06-30 US US10/881,589 patent/US7265222B2/en not_active Expired - Lifetime

Patent Citations (3)

Also Published As

Similar Documents

Legal Events